Emerging evidence suggests that the reduced capacity of the microbiota to produce the AHR activating metabolites could be a key factor in metabolic syndrome [242], the mechanism of which might be associated with intestinal barrier dysfunctions caused by decreased production of GLP-1 and IL-22, thereby leading to chronic inflammation, liver steatosis, and insulin resistance [277,278]. This evidence concerns the gene IL22 and Insulin resistance.